AAAAAA

   
Results: 1-12 |
Results: 12
VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) - PLASMA IS THE PLACE TO BE
Authors: WYNENDAELE W DERUA R HOYLAERTS MF PAWINSKI A WAELKENS E DEBRUIJN EA MERLEVEDE W PARIDAENS R VANOOSTEROM AT
Citation: W. Wynendaele et al., VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) - PLASMA IS THE PLACE TO BE, Annals of oncology, 9, 1998, pp. 590-590
CHOICE OF END-POINTS AND SAMPLE-SIZE FOR PROPHYLACTIC TRIALS IN TATL BLADDER-CANCER - RESULTS BASED ON A COMBINED ANALYSIS OF EORTC AND MRCRANDOMIZED TRIALS
Authors: SYLVESTER RJ PARMAR MKB KURTH K OOSTERLINCK W PAWINSKI A VANDERMEIJDEN AP
Citation: Rj. Sylvester et al., CHOICE OF END-POINTS AND SAMPLE-SIZE FOR PROPHYLACTIC TRIALS IN TATL BLADDER-CANCER - RESULTS BASED ON A COMBINED ANALYSIS OF EORTC AND MRCRANDOMIZED TRIALS, The Journal of urology, 159(5), 1998, pp. 539-539
THE 3-MONTH RECURRENCE AS A PROGNOSTIC FACTOR FOR THE LONG-TERM OUTCOME IN TATL BLADDER-CANCER - RESULTS OF A COMBINED ANALYSIS OF EORTC AND MRC RANDOMIZED TRIALS OF PROPHYLACTIC TREATMENT
Authors: COLLETTE L SYLVESTER RJ DENIS LJ BOUFFIOUX C KURTH K VANDERMEIJDEN AP PARMAR MKB PAWINSKI A
Citation: L. Collette et al., THE 3-MONTH RECURRENCE AS A PROGNOSTIC FACTOR FOR THE LONG-TERM OUTCOME IN TATL BLADDER-CANCER - RESULTS OF A COMBINED ANALYSIS OF EORTC AND MRC RANDOMIZED TRIALS OF PROPHYLACTIC TREATMENT, The Journal of urology, 159(5), 1998, pp. 540-540
AN EORTC PHASE-II STUDY OF THE EFFICACY AND SAFETY OF LINOMIDE IN THETREATMENT OF ADVANCED RENAL-CELL CARCINOMA
Authors: PAWINSKI A VANOOSTEROM AT DEWIT R FOSSA S CROLES J SVEDBERG A LENTZ MA DEMULDER PHM
Citation: A. Pawinski et al., AN EORTC PHASE-II STUDY OF THE EFFICACY AND SAFETY OF LINOMIDE IN THETREATMENT OF ADVANCED RENAL-CELL CARCINOMA, European journal of cancer, 33(3), 1997, pp. 496-499
ELEVATED LEVELS OF THE ANGIOGENIC CYTOKINES BASIC FIBROBLAST GROWTH-FACTOR AND VASCULAR ENDOTHELIAL GROWTH-FACTOR IN SERA OF CANCER-PATIENTS
Authors: DIRIX LY VERMEULEN PB PAWINSKI A PROVE A BENOY I DEPOOTER C MARTIN M VANOOSTEROM AT
Citation: Ly. Dirix et al., ELEVATED LEVELS OF THE ANGIOGENIC CYTOKINES BASIC FIBROBLAST GROWTH-FACTOR AND VASCULAR ENDOTHELIAL GROWTH-FACTOR IN SERA OF CANCER-PATIENTS, British Journal of Cancer, 76(2), 1997, pp. 238-243
ORAL IFOSFAMIDE MESNA VERSUS INTRAVENOUS IFOSFAMIDE/MESNA IN NON-SMALL-CELL LUNG-CANCER - A RANDOMIZED PHASE-II TRIAL OF THE EORTC LUNG-CANCER COOPERATIVE GROUP/
Authors: MANEGOLD C DRINGS P PAWINSKI A LENTZ MA VANGLABBEKE M VANZANDWIJK N BACHMANN P SCHNAARS Y SKACEL Z ZATLOUKAL P DOLENSKY J JACKEVICIUS A PETRUZELKA L GIACCONE G
Citation: C. Manegold et al., ORAL IFOSFAMIDE MESNA VERSUS INTRAVENOUS IFOSFAMIDE/MESNA IN NON-SMALL-CELL LUNG-CANCER - A RANDOMIZED PHASE-II TRIAL OF THE EORTC LUNG-CANCER COOPERATIVE GROUP/, Annals of oncology, 7(6), 1996, pp. 637-639
A COMBINED ANALYSIS OF ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER, AND MEDICAL-RESEARCH-COUNCIL RANDOMIZED CLINICAL-TRIALS FOR THE PROPHYLACTIC TREATMENT OF STAGE TAT1 BLADDER-CANCER
Authors: PAWINSKI A SYLVESTER R KURTH KH BOUFFIOUX C VANDERMEIJDEN A PARMAR MKB BIJNENS L
Citation: A. Pawinski et al., A COMBINED ANALYSIS OF ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER, AND MEDICAL-RESEARCH-COUNCIL RANDOMIZED CLINICAL-TRIALS FOR THE PROPHYLACTIC TREATMENT OF STAGE TAT1 BLADDER-CANCER, The Journal of urology, 156(6), 1996, pp. 1934-1940
A COMBINED ANALYSIS OF ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER, AND MEDICAL-RESEARCH-COUNCIL RANDOMIZED CLINICAL-TRIALS FOR THE PROPHYLACTIC TREATMENT OF STAGE TAT1 BLADDER-CANCER - REPLY
Authors: PAWINSKI A SYLVESTER R KURTH KH BOUFFIOUX C VANDERMEIJDEN A PARMAR MKB BIJNENS L
Citation: A. Pawinski et al., A COMBINED ANALYSIS OF ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER, AND MEDICAL-RESEARCH-COUNCIL RANDOMIZED CLINICAL-TRIALS FOR THE PROPHYLACTIC TREATMENT OF STAGE TAT1 BLADDER-CANCER - REPLY, The Journal of urology, 156(6), 1996, pp. 1941-1941
THE EFFICACY AND SAFETY OF LINOMIDE IN THE TREATMENT OF RENAL-CELL CARCINOMA [RCC] - AN EORTC PHASE-II STUDY
Authors: PAWINSKI A VANOOSTEROM AT DEMULDER PHM STOTER G SVEDBERG A
Citation: A. Pawinski et al., THE EFFICACY AND SAFETY OF LINOMIDE IN THE TREATMENT OF RENAL-CELL CARCINOMA [RCC] - AN EORTC PHASE-II STUDY, European journal of cancer, 31A, 1995, pp. 461-461
HIGH-DOSE EPIRUBICIN IS EFFECTIVE IN MEASURABLE METASTATIC PROSTATE-CANCER - A PHASE-II STUDY OF THE EORTC GENITOURINARY GROUP
Authors: BRAUSI M JONES WG FOSSA SD DEMULDER PHM DROZ JP LENTZ MA VANGLABBEKE M PAWINSKI A
Citation: M. Brausi et al., HIGH-DOSE EPIRUBICIN IS EFFECTIVE IN MEASURABLE METASTATIC PROSTATE-CANCER - A PHASE-II STUDY OF THE EORTC GENITOURINARY GROUP, European journal of cancer, 31A(10), 1995, pp. 1622-1626
A REPORT COMPARING THE USE OF TROPISETRON (NAVOBAN), A 5-HT3 ANTAGONIST, WITH A STANDARD ANTIEMETIC REGIMEN OF DEXAMETHASONE AND METOCLOPRAMIDE IN CISPLATIN-TREATED PATIENTS UNDER CONDITIONS OF SEVERE EMESIS
Authors: MADEJ G KRZAKOWSKI M PAWINSKI A LASOTA W ROGOWSKI W SKONECZNA I
Citation: G. Madej et al., A REPORT COMPARING THE USE OF TROPISETRON (NAVOBAN), A 5-HT3 ANTAGONIST, WITH A STANDARD ANTIEMETIC REGIMEN OF DEXAMETHASONE AND METOCLOPRAMIDE IN CISPLATIN-TREATED PATIENTS UNDER CONDITIONS OF SEVERE EMESIS, Seminars in oncology, 21(5), 1994, pp. 3-6
A COMPARATIVE-STUDY OF THE USE OF NAVOBAN (ICS 205-930), A 5-HT3 ANTAGONIST, VERSUS A STANDARD ANTIEMETIC REGIMEN OF DEXAMETHASONE AND METOCLOPRAMIDE IN THE TREATMENT OF CISPLATIN-CONTAINING CHEMOTHERAPY
Authors: MADEJ G KRZAKOWSKI M PAWINSKI A LASOTA W ROGOWSKI W SKONECZNA I
Citation: G. Madej et al., A COMPARATIVE-STUDY OF THE USE OF NAVOBAN (ICS 205-930), A 5-HT3 ANTAGONIST, VERSUS A STANDARD ANTIEMETIC REGIMEN OF DEXAMETHASONE AND METOCLOPRAMIDE IN THE TREATMENT OF CISPLATIN-CONTAINING CHEMOTHERAPY, Drug investigation, 6(3), 1993, pp. 162-169
Risultati: 1-12 |